Aditxt, Inc., a biotech company, develops technologies focuses on improving the health of the immune system through immune mapping and reprogramming. It develops AditxtScore that allows individuals to understand, manage, and monitor their immune profiles in order to be informed about attacks on or by their immune system; and Apoptotic DNA Immunotherapy, a nucleic acid-based technology that utilizes an approach that mimics the way the body naturally induces tolerance to its own tissues. The company is also developing ADi products for organ transplantation, including skin grafting, autoimmune diseases, and allergies. Aditxt, Inc. has a license agreement with Loma Linda University and Leland Stanford Junior University. The company was formerly known as ADiTx Therapeutics, Inc. and changed its name to Aditxt, Inc. in July 2021. Aditxt, Inc. was incorporated in 2017 and is headquartered in Richmond, Virginia.

Dr. Dolly B. Tyan Ph.D.

Senior Vice President of Clinical Development  Transplantation

Mr. Ge  Chen M.D., M.S.

Senior Vice President of Preclinical Research & Discovery

Ms. Corinne D. Pankovcin CPA, M.B.A.

Chief Commercialization Officer

Dr. Shahrokh  Shabahang D.D.S., M.S., Ph.D.

Co-Founder, Chief Innovation Officer, Secretary & Director

Ms. Jennifer  Lee

Director of Human Resources

Mr. Amro A. Albanna

Co-Founder, Chairman & Chief Executive Officer

Mr. Thomas J. Farley CPA

Chief Financial Officer

Ms. Rowena  Albanna

Chief Operating Officer

バイオテクノロジー

Aditxt, Inc.

Aditxt, Inc. 経営体制

経営情報